// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Bambi-deficiency enhances adipose tissue browning, ameliorates dyslipidemia and confers protection against atherosclerosis

C. Lee - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

Evithrom

Biomarkers in COVID-19: Association with disease severity and outcomes

M. Peralta - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Bleed Outcomes in the Moderate and Mild Hemophilia A Population Without Prophylactic Treatment in CHESS II and CHESS PAEDs

K. Khair - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

N/A

Bleeding diathesis in a girl with biallelic variants in RASGRP2 gene affecting platelet CalDAG-GEFI function

J. Frontroth - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Bleeding Rates in Severe Non-inhibitor Haemophilia A Patients Across US, EU4&UK and Japan

A. Amirah - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

N/A

Both α- and γ-chain crosslinks mediated by FXIIIa affect fibrin fibre resistance to rupture

T. Feller - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Evithrom

Burden of Illness in Patients With von Willebrand Disease Receiving Prophylaxis Versus Potential Prophylaxis-Eligible Patients: A Post-Hoc Analysis of A European Socioeconomic Study

P. Du - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Ca2+ and Zn2+ binding to human Protein Z (PZ) induces structural changes that augments its lipid binding

T. Sengupta - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

CD36-dependent metabolic rewiring and mitochondrial dysfunction in platelets in response to hyperlipidaemia.

L. Cheah - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Cell-based high throughput screening to identify FDA/EMA approved drugs that inhibit the endothelial pro-thrombotic switch during severe COVID19 infection

D. Jones - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Changes in circulating H3 Histone levels during Extracorporeal Membrane Oxygenation in patients with severe respiratory failure with correlation to haemostatic complications

A. Doyle - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Changes in fibrinolysis during Extracorporeal Membrane Oxygenation in critically ill adult patients

A. Doyle - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Fibrinogen (IV)

Changes in immature platelet fraction after major trauma: a prospective cohort study

A. Rossetto - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Trauma

N/A

Changes in VWF, ADAMTS13, and Complement in Preeclampsia, HELLP syndrome and Other Obstetric Complications: a Single Centre Observational Study.

L. Neave - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

HELLP syndrome

N/A

Changing management of superficial vein thrombosis: a 5 year single site observational study

R. Gooding - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Superficial Vein Thrombosis

Fondaparinux sodium

Changing Pattern of Venous Thrombosis events in 2021 associated with COVID in a teaching hospital

H. Rowswell - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Characterisation of 17 Novel Von Willebrand Factor Missense Mutations

M. Appiah - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Characterisation of anti-TFPI Kunitz domain 3 antibodies that selectively inhibit protein S cofactor function.

A. Petri - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

folitixorin calcium

Characterising Endothelial Colony-Forming Cells in The Context Of HIV: People Living with HIV Have Elevated Endothelial Colony-Forming Cell Frequency

A. Khawaja - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Clinical characteristics and management of children with severe factor VII deficiency- analysis of a United Kingdom cohort

T. Biss - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Factor VII deficiency

N/A

Copyright © 2026. QuantiNova All rights reserved